GLP1R and colorectal neoplasm: This finding would provide insight into the clinical practice that (1) not every GLP-1 receptor agonist would be safe regarding the risk of colorectal tumor and (2) semaglutide should be used with caution about colorectal tumor risk when the dosage reaches an upper limit (i.e., 2.4 mg/week) in inject form.